Shares Outstanding (Quarterly) Chart

View Shares Outstanding (Quarterly) for ZVRA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shares Outstanding (Quarterly) Chart
Start Trial

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2014. Start Trial.
Date Value
June 30, 2026 59.34M
March 31, 2026 59.11M
December 31, 2025 56.85M
September 30, 2025 56.22M
June 30, 2025 55.08M
March 31, 2025 54.68M
December 31, 2024 53.67M
September 30, 2024 53.23M
June 30, 2024 41.99M
March 31, 2024 41.85M
December 31, 2023 41.53M
September 30, 2023 36.21M
June 30, 2023 33.93M
March 31, 2023 33.88M
December 31, 2022 35.45M
September 30, 2022 34.50M
June 30, 2022 34.49M
March 31, 2022 34.42M
December 31, 2021 35.01M
September 30, 2021 35.32M
June 30, 2021 34.98M
March 31, 2021 28.48M
December 31, 2020 4.537M
September 30, 2020 4.532M
Date Value
June 30, 2020 4.202M
March 31, 2020 3.548M
December 31, 2019 2.272M
September 30, 2019 2.024M
June 30, 2019 1.804M
March 31, 2019 1.749M
December 31, 2018 1.654M
September 30, 2018 1.003M
June 30, 2018 0.9941M
March 31, 2018 0.9441M
December 31, 2017 0.9161M
September 30, 2017 0.9161M
June 30, 2017 0.9161M
March 31, 2017 0.9154M
December 31, 2016 0.9154M
September 30, 2016 0.9154M
June 30, 2016 0.9154M
March 31, 2016 0.9062M
December 31, 2015 0.9057M
September 30, 2015 0.8901M
June 30, 2015 0.8893M
March 31, 2015 0.1494M
December 31, 2014 0.8414M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Innoviva, Inc. 72.64M
Collegium Pharmaceutical, Inc. 32.50M
Johnson & Johnson 2.408B
Ligand Pharmaceuticals, Inc. 19.92M
Harrow, Inc. 37.48M